Orencia (abatacept) Letter of Medical Necessity
Orencia (abatacept) frequently faces step-therapy denials requiring prior TNF inhibitor failure. Citing seropositive RA with extra-articular features or specific contraindications to TNF therapy can support an exception in a Letter of Medical Necessity.
FDA-Approved Indications
- ● rheumatoid arthritis
- ● psoriatic arthritis
- ● polyarticular juvenile idiopathic arthritis
- ● prophylaxis of acute graft-versus-host disease
Why Orencia Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: TNF inhibitor not tried first
- 2. Active TB screening not documented
- 3. Disease activity score not on file
- 4. Concurrent biologic or JAK inhibitor use
- 5. Self-injection (SC) vs IV infusion site-of-care conflict
What to Include in a Orencia Letter of Medical Necessity
Document confirmed RA or PsA diagnosis, seropositivity status (anti-CCP, RF), prior csDMARD and TNF inhibitor trials with dates and reason for discontinuation, baseline disease activity, TB screening, and rationale for T-cell costimulation modulation (e.g., demyelinating disease, severe infection history, RA-ILD where Orencia is preferred).
Key clinical evidence to cite:
- ✓ AMPLE trial — non-inferior to adalimumab in MTX-IR RA
- ✓ AVERT trial — sustained remission in early RA
- ✓ ASTRAEA trial — efficacy in PsA
Relevant guidelines:
- 📖 ACR 2021 RA Guidelines
- 📖 GRAPPA 2021 PsA Recommendations
- 📖 ACR 2022 JIA Guidelines
Orencia Prior Authorization Criteria
Standard criteria across major US payers for Orencia. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: TNF inhibitor not tried first
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Orencia
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Orencia Prior Authorization FAQ
Why was my Orencia prior authorization denied?
The most common denial reasons for Orencia are: Step therapy: TNF inhibitor not tried first; Active TB screening not documented; Disease activity score not on file; Concurrent biologic or JAK inhibitor use; Self-injection (SC) vs IV infusion site-of-care conflict.
What should a Orencia Letter of Medical Necessity include?
Document confirmed RA or PsA diagnosis, seropositivity status (anti-CCP, RF), prior csDMARD and TNF inhibitor trials with dates and reason for discontinuation, baseline disease activity, TB screening, and rationale for T-cell costimulation modulation (e.g., demyelinating disease, severe infection history, RA-ILD where Orencia is preferred).
Which payers cover Orencia?
Orencia is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Humana, Medicare Part B, though formulary tier and prior authorization criteria vary.